Furthermore, oral treatment of AD mice with an apoA-I mimetic improves memory and reduces amyloid burden [12], intravenous treatment with reconstituted human HDL or recombinant apoA-I Milano reduces soluble Aβ levels in the brains of AD mice [13,14], and either treatment reduces CNS inflammation [12,14]. The gene discussed is APOA1; the disease is Alzheimer disease.